Calidi Biotherapeutics Inc (CLDI)

Currency in USD
0.1693
-0.0057(-3.26%)
Closed·
0.1684-0.0009(-0.53%)
·
CLDI is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
0.16230.1699
52 wk Range
0.157719.2000
Key Statistics
Prev. Close
0.1693
Open
0.1684
Day's Range
0.1623-0.1699
52 wk Range
0.1577-19.2
Volume
2.39M
Average Volume (3m)
4.56M
1-Year Change
-95.8975%
Book Value / Share
0.45
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
CLDI Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
120.0048
Upside
+70,782.93%
Members' Sentiments
Bearish
Bullish
ProTips
Quickly burning through cash

Calidi Biotherapeutics Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Neutral
Technical Indicators
Sell
Moving Averages
Neutral

Analyst Ratings

1 Buy
0 Hold
0 Sell
Ratings:
1 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 120.0048
(+70,782.93% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate

Earnings

Latest Release
May 14, 2026
EPS / Forecast
-0.43 / --
Revenue / Forecast
-- / --
EPS Revisions
Last 90 days

CLDI Income Statement

Compare CLDI to Peers and Sector

Metrics to compare
CLDI
Peers
Sector
Relationship
P/E Ratio
−0.1x−2.3x−0.5x
PEG Ratio
0.00−0.190.00
Price/Book
0.5x2.9x2.6x
Price / LTM Sales
-16.4x3.0x
Upside (Analyst Target)
-186.4%58.6%
Fair Value Upside
Unlock18.6%10.2%Unlock

Calidi Biotherapeutics, Inc., a biotechnology company, develops targeted therapies to deliver genetic medicines to distal sites of disease. The company offers CLD-101, which is in Phase 1b/2 clinical trial for the treatment of newly diagnosed high grade glioma, as well as in Phase 1 dose-escalation clinical trial for recurrent high-grade glioma; CLD-201 product for solid tumors, such as breast cancer, head and neck cancer, and sarcoma; and CLD-401 for the treatment of metastatic solid tumors. It also offers oncolytic virus platforms, such as NeuroNova and SuperNova. Calidi Biotherapeutics, Inc. was founded in 2014 and is headquartered in San Diego, California.

Ownership

Ownership Overview

Type
Common Stock Held% of Shares OutstandingMarket Value
Mutual Funds & ETFs
74.09K0.48%12.54K
Other Institutional Investors
3.21M20.89%544.02K
Public Companies & Retail Investors
12.09M78.62%2.05M
Total
15.38M100.00%2.6M

Top Holders

Holder
% of holding
Shares Held
Date Reported
Value (In 1,000s)
Armistice Capital Master Fund Ltd.7.23%1,111,732188
Armistice Capital LLC5.72%879,000149

People Also Watch

1.4500
HUBC
-3.97%
0.2435
TOVX
+0.74%
1.0500
ONCO
+10.89%
1.50
LZMH
+0.67%

FAQ

What Is the Calidi Biotherapeutics (CLDI) Stock Price Today?

The Calidi Biotherapeutics stock price today is 0.1693 USD.

What Stock Exchange Does Calidi Biotherapeutics Trade On?

Calidi Biotherapeutics is listed and trades on the New York Stock Exchange.

What Is the Stock Symbol for Calidi Biotherapeutics?

The stock symbol for Calidi Biotherapeutics is "CLDI."

What Is the Calidi Biotherapeutics Market Cap?

As of today, Calidi Biotherapeutics market cap is 2.6000M USD.

What Is Calidi Biotherapeutics's Earnings Per Share (TTM)?

The Calidi Biotherapeutics EPS (TTM) is -3.9627.

When Is the Next Calidi Biotherapeutics Earnings Date?

Calidi Biotherapeutics will release its next earnings report on Aug 18, 2026.

From a Technical Analysis Perspective, Is CLDI a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.

How Many Times Has Calidi Biotherapeutics Stock Split?

Calidi Biotherapeutics has split 2 times.

How Many Employees Does Calidi Biotherapeutics Have?

Calidi Biotherapeutics has 29 employees.

What is the current trading status of Calidi Biotherapeutics (CLDI)?

As of Jun 11, 2026, Calidi Biotherapeutics (CLDI) is trading at a price of 0.1693 USD, with a previous close of 0.1693 USD. The stock has fluctuated within a day range of 0.1623 USD to 0.1699 USD, while its 52-week range spans from 0.1577 USD to 19.2000 USD.

What Is Calidi Biotherapeutics (CLDI) Price Target According to Analysts?

The average 12-month price target for Calidi Biotherapeutics is 120.0048 USD, with a high estimate of 120.0048 USD and a low estimate of 120.0048 USD. 1 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +70,782.93% Upside potential.

What Is the CLDI Premarket Price?

CLDI's last pre-market stock price is 0.1684 USD. The pre-market share volume is 2,790,000.0000, and the stock has decreased by -0.0009, or -0.5300%.

What Is the CLDI After Hours Price?

CLDI's last after hours stock price is 0.1962 USD, the stock has decreased by 0.0269, or 15.8900%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.